While the study did not address mesothelioma directly, a new report from Nature Medicine concluded that genetic sequencing could be used as a roadmap to develop essential targeted treatments. Each individual’s cancer cells are like a thumbprint with a unique genetic profile. Once a genetic profile is established it then enables doctors to check that profile against a database of other tumor genetic profiles to see what therapies have had the greatest success against that tumor as well as what treatments failed.
The research into the genetic mapping was conducted at Memorial Sloan Kettering Cancer Center (MSKCC) where the group has sequenced over 10,000 tumors. The findings are especially relevant to those patients with advanced stage cancer. Because of the long latency period mesothelioma is discovered at an advanced stage so there is a hope that MSKCC research could have a positive impact on the asbestos caused cancer.
Regarding the group’s findings, Michael Berger, associate director of the Center for Molecular Oncology at MSKCC said, “What’s unique about our data set is that we collected samples from patients with advanced, metastatic cancer. A lot of the other large-scale genomic databases look at untreated tumors when patients are first diagnosed, and they provide a different genomic landscape and makeup than advanced cancers which are collected after several rounds of therapy.”
The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.
Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers
